Bris­tol-My­ers scores fresh brag­ging rights with PhI­II gas­tric can­cer suc­cess for Op­di­vo

Bris­tol-My­ers Squibb has grabbed some bad­ly need­ed new brag­ging rights in the check­point space, an­nounc­ing Thurs­day morn­ing that in­ves­ti­ga­tors reaped pos­i­tive over­all sur­vival da­ta from their Phase III study on gas­tric can­cer.

Its claim to fame: This is the first check­point to pro­vide piv­otal OS da­ta for un­re­sectable ad­vanced or re­cur­rent drug-re­sis­tant gas­tric can­cer, though we won’t know what that is un­til in­ves­ti­ga­tors roll the da­ta out an up­com­ing con­fer­ence.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER